ConductScience.org, home

Comparison · NCT00795366-sae

AVP, Arginine Vasopressin vs Standard Catecholamine: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. AVP, Arginine Vasopressin vs Standard Catecholamine: serious adverse events. Trial comparisons, record NCT00795366-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00795366-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1430.06720.278wilson
Risk in group 20.1110.05190.222wilson
Risk difference, group 1 minus group 20.0317-0.1020.18newcombe hybrid score
Risk ratio, group 1 over group 21.290.4473.7log
Odds ratio, group 1 over group 21.330.3974.48log
Number needed to harm, for one more participant with a serious adverse event on AVP, Arginine Vasopressin than on Standard Catecholamine31.5from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1AVP, Arginine VasopressinVasopressin, arginine vasopressin: Titrated to cerebral perfusion pressure greater than 60 mm Hg642EG000
Group 2Standard CatecholamineStandard catecholamine: Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.654EG001

Harm

What it counts
Total, serious adverse events
Time frame
Adverse events were collected during the primary study period as the first 5 days of intracranial pressure monitoring while outcome data was also collected from admission until discharge from the hospital.

Source ClinicalTrials.gov

Trial

Title
Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients
NCT number
NCT00795366
Phases
NA
Conditions
Traumatic Brain Injury
Interventions
arginine vasopressin, Standard catecholamine
Lead sponsor
University of Miami
Results first posted
2014-12-12

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00795366-sae